Fragment‐end sequence architecture of cell‐free DNA and its association with tumour DNA in non‐small cell lung cancer
Clinical and Translational Medicine · 2026-11 · 16 (11)
DOI: 10.1002/ctm2.70901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 14.11.2026. Verfasst von Dhruv Das und 5 weiteren Autor:innen. Beteiligte Einrichtung: Applied Genomics Section, Bioscience Group, Bhabha Atomic Research Centre, Mumbai, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell-Free Nucleic Acids, Circulating Tumor DNA. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Atomic Energy (DAE), India.
Abstract (Originalsprache)
Introduction
Circulating cell‐free DNA (cfDNA) fragmentation patterns provide a promising source of molecular information for liquid biopsy applications. However, the sequence features underlying fragmentation and their relationship to tumour‐derived DNA remain incompletely understood. Here, we characterized fragment‐end sequence signatures of extracellular cfDNA across cell lines, extracellular compartments, stress conditions and plasma from patients with non‐small cell lung cancer (NSCLC). Methods cfDNA derived from cell lines was characterized using Oxford Nanopore sequencing, followed by fragment‐end analysis. Publicly available Nanopore cfDNA datasets from healthy individuals and NSCLC patients were analyzed to examine dinucleotide patterns and derive a motif ratio index. These signatures were further assessed for their association with estimated ctDNA abundance in an independent cohort of 50 EGFR‐mutant NSCLC patients.
Results
Nanopore sequencing of A549, H460 and WI38 cell‐line cfDNA revealed reproducible end‐motif patterns, with enrichment of AT‐, GT‐ and CT‐containing termini. Analysis of plasma cfDNA from healthy individuals showed distinct end‐motif profiles from cell‐line‐derived cfDNA, with separation maintained after reducing 4‐mer motifs to 5′‐terminal dinucleotide features. An exploratory motif ratio based on these patterns showed a modest increase in lung cancer patients compared with healthy individuals. In an independent Illumina cohort of 50 NSCLC patients with activating EGFR mutations, 5′‐terminal dinucleotide frequencies were associated with estimated circulating tumour DNA (ctDNA) abundance using cross‐validated LASSO (Least Absolute Shrinkage and Selection Operator) regression (Spearman ρ = .73, p = 3.35 × 10 ‒9 ). The predefined motif ratio showed a strong correlation with estimated ctDNA concentration (Spearman ρ = .76, p = 1.89 × 10 ‒10 ).
Conclusion
These findings suggest that simple, interpretable cfDNA end‐motif signatures capture sequence features associated with ctDNA abundance and warrant further validation for non‐invasive cancer monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Applied Genomics Section, Bioscience Group, Bhabha Atomic Research Centre, Mumbai, India.
- Homi Bhabha National Institute, Mumbai, India.
ORCID-Profile: Rajani Kant Chittela
Förderung
- Department of Atomic Energy (DAE), India
Zitieren
APA
Das, D., Gupta, P., Tambade, R., Hassan, P. A., Rao, A. V. S. S. N., & Chittela, R. K. (2026). Fragment‐end sequence architecture of cell‐free DNA and its association with tumour DNA in non‐small cell lung cancer. Clinical and Translational Medicine, 16(11). https://doi.org/10.1002/ctm2.70901
Vancouver
Das D, Gupta P, Tambade R, Hassan PA, Rao AVSSN, Chittela RK. Fragment‐end sequence architecture of cell‐free DNA and its association with tumour DNA in non‐small cell lung cancer. Clinical and Translational Medicine. 2026;16(11). doi:10.1002/ctm2.70901
BibTeX
@article{Das2026,
author = {Das, Dhruv and Gupta, Prachi and Tambade, Rahul and Hassan, P A and Rao, A V S S Narayana and Chittela, Rajani Kant},
title = {Fragment‐end sequence architecture of cell‐free DNA and its association with tumour DNA in non‐small cell lung cancer},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {11},
doi = {10.1002/ctm2.70901}
}
EUVIMED